1
|
Tee PYE, Krishnan T, Cheong XT, Maniam SAP, Looi CY, Ooi YY, Chua CLL, Fung SY, Chia AYY. A review on the cultivation, bioactive compounds, health-promoting factors and clinical trials of medicinal mushrooms Taiwanofungus camphoratus, Inonotus obliquus and Tropicoporus linteus. Fungal Biol Biotechnol 2024; 11:7. [PMID: 38987829 PMCID: PMC11238383 DOI: 10.1186/s40694-024-00176-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2024] [Accepted: 06/09/2024] [Indexed: 07/12/2024] Open
Abstract
Medicinal mushrooms, such as Taiwanofungus camphoratus, Inonotus obliquus, and Tropicoporus linteus, have been used in traditional medicine for therapeutic purposes and promotion of overall health in China and many East Asian countries for centuries. Modern pharmacological studies have demonstrated the large amounts of bioactive constituents (such as polysaccharides, triterpenoids, and phenolic compounds) available in these medicinal mushrooms and their potential therapeutic properties. Due to the rising demand for the health-promoting medicinal mushrooms, various cultivation methods have been explored to combat over-harvesting of the fungi. Evidence of the robust pharmacological properties, including their anticancer, hypoglycemic, hypolipidemic, antioxidant, and antiviral activities, have been provided in various studies, where the health-benefiting properties of the medicinal fungi have been further proven through numerous clinical trials. In this review, the cultivation methods, available bioactive constituents, therapeutic properties, and potential uses of T. camphoratus, I. obliquus and T. linteus are explored.
Collapse
Affiliation(s)
- Phoebe Yon Ern Tee
- School of Biosciences, Faculty of Health and Medical Sciences, Taylor's University, 47500, Selangor, Malaysia
| | - Thiiben Krishnan
- School of Biosciences, Faculty of Health and Medical Sciences, Taylor's University, 47500, Selangor, Malaysia
| | - Xin Tian Cheong
- School of Biosciences, Faculty of Health and Medical Sciences, Taylor's University, 47500, Selangor, Malaysia
| | - Snechaa A P Maniam
- School of Biosciences, Faculty of Health and Medical Sciences, Taylor's University, 47500, Selangor, Malaysia
| | - Chung Yeng Looi
- School of Biosciences, Faculty of Health and Medical Sciences, Taylor's University, 47500, Selangor, Malaysia
| | - Yin Yin Ooi
- School of Biosciences, Faculty of Health and Medical Sciences, Taylor's University, 47500, Selangor, Malaysia
| | - Caroline Lin Lin Chua
- School of Biosciences, Faculty of Health and Medical Sciences, Taylor's University, 47500, Selangor, Malaysia
| | - Shin-Yee Fung
- Department of Molecular Medicine, Faculty of Medicine Building, University of Malaya, 50603, Kuala Lumpur, Malaysia
| | - Adeline Yoke Yin Chia
- School of Biosciences, Faculty of Health and Medical Sciences, Taylor's University, 47500, Selangor, Malaysia.
| |
Collapse
|
2
|
Liao YT, Huang KW, Chen WJ, Lai TH. A Botanical Drug Extracted From Antrodia cinnamomea: A First-in-human Phase I Study in Healthy Volunteers. JOURNAL OF THE AMERICAN NUTRITION ASSOCIATION 2023; 42:274-284. [PMID: 35512765 DOI: 10.1080/07315724.2022.2032868] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
LEAC-102 is an emerging drug extracted from the medicinal fungus Antrodia cinnamomea (AC), which is traditionally used to ameliorate fatigue and liver disorders arising from excessive alcohol consumption. AC has been used as a health product with an immunomodulatory function, but its anticancer effect has not been applied in clinical therapy as a drug. This first-in-human study examined the safety and tolerability of LEAC-102 as a new drug in healthy adults. This standard 3 + 3 dose-escalation study included 18 participants administered LEAC-102 at doses of 597.6, 1195.2, 1792.8, 2390.4, or 2988 mg/day for 1 month plus 7 days of safety follow-up. The maximum planned dose was 2988 mg. Dose-limiting toxicity (DLT) was monitored from the start of LEAC-102 administration up to the final visit. The dose of LEAC-102 was escalated to the subsequent cohort as long as there was no DLT in the previous cohort. Tolerability, clinical status, safety (by laboratory parameters), and adverse event occurrence were documented weekly during the treatment and 1 week after the conclusion of the treatment. All clinical biochemistry profiles were in the normal range, and no serious adverse effects were observed. The maximum tolerated dose of LEAC-102 was determined to be 2988 mg/day because one participant experienced urticaria. Additionally, our exploratory objectives revealed that LEAC-102 significantly elevated natural killer, natural killer T, and dendritic cells in a dose-dependent manner, activated effector T cells, and upregulated programmed cell death-1 expression. The outcomes suggested that LEAC-102 was well tolerated and safe in healthy adults and exhibited potential immunomodulatory function. Supplemental data for this article is available online at https://doi.org/10.1080/07315724.2022.2032868 .
Collapse
Affiliation(s)
- Yu-Tso Liao
- Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei City, Taiwan.,Division of Colorectal Surgery, Department of Surgery, Biomedical Park Hospital, National Taiwan University Hospital, Taipei City, Taiwan
| | - Kai-Wen Huang
- Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei City, Taiwan.,Department of Surgery, National Taiwan University Hospital, Taipei City, Taiwan.,Hepatitis Research Center, National Taiwan University Hospital, Taipei City, Taiwan
| | | | | |
Collapse
|
3
|
Ho CY, Kuan CM, Hsu PK. Hepatoprotective effect of Antrodia Cinnamomea mycelia extract in subhealth Japanese adults: a randomized, double-blind, placebo-controlled clinical study. J Diet Suppl 2022; 20:939-949. [PMID: 36476310 DOI: 10.1080/19390211.2022.2152147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Antrodia cinnamomea, a unique Taiwanese fungus (mushroom), has demonstrated the hepatoprotective activities in animals with liver injury. Nevertheless, there are few studies reporting the efficacy of the fungus in subhealth subjects (alanine aminotransferase (ALT) levels between 31 and 50 U/L and aspartate aminotransferase (AST) levels ≤ 50 U/L). In this study, we assessed the ameliorating effect of a A. cinnamomea mycelia extract (ACME) on liver health in asymptomatic individuals with marginally high ALT levels. Forty-four eligible Japanese adults were enrolled in this randomized, double-blind, placebo-controlled clinical study and instructed to take an ACME capsule (250 mg of ACME powder) or a placebo capsule daily for 12 weeks. The primary outcomes (i.e. ALT and AST) were analyzed at 0, 4, 8, and 12 weeks. No treatment-related adverse effects were observed throughout this study. In efficacy analyses with the per-protocol (PP) cohort of participants, there were no significant changes in ALT and AST levels within and between groups. However, subgroup analysis showed that ACME could significantly improve the mean ALT level of regular drinkers, consuming alcoholic drinks more than twice a week, after the study in comparison with the result of the placebo group. This exploratory study indicated that the ACME might effectively improve liver health in regular drinkers.
Collapse
Affiliation(s)
- Chun-Yi Ho
- Department of Research and Development, Greenyn Biotechnology Co., Ltd, Taichung City, Taiwan
| | - Chen-Meng Kuan
- Department of Research and Development, Greenyn Biotechnology Co., Ltd, Taichung City, Taiwan
| | - Pang-Kuei Hsu
- Department of Research and Development, Greenyn Biotechnology Co., Ltd, Taichung City, Taiwan
| |
Collapse
|
4
|
Turck D, Bohn T, Castenmiller J, De Henauw S, Hirsch-Ernst KI, Maciuk A, Mangelsdorf I, McArdle HJ, Naska A, Pelaez C, Pentieva K, Siani A, Thies F, Tsabouri S, Vinceti M, Cubadda F, Frenzel T, Heinonen M, Marchelli R, Neuhäuser-Berthold M, Poulsen M, Prieto Maradona M, Schlatter JR, van Loveren H, Turla E, Knutsen HK. Safety of freeze-dried mycelia of Antrodia camphorata as a novel food pursuant to regulation (EU) 2015/2283. EFSA J 2022; 20:e07380. [PMID: 35784815 PMCID: PMC9240966 DOI: 10.2903/j.efsa.2022.7380] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on freeze-dried mycelia of Antrodia camphorata as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is produced by solid-state cultivation from tissue cultures derived from the fungus Antrodia camphorata. The applicant intends to market the NF in food supplements at a maximum dose of 990 mg per day. The target population is the general population. The NF mainly consists of carbohydrates, proteins and fats, and it contains numerous constituents, such as β-glucans, antroquinonol and triterpenoids. Taking into account the composition of the NF and the proposed conditions of use, the consumption of the NF is not nutritionally disadvantageous. There are no concerns regarding genotoxicity of the NF. Based on a 90-day repeated dose toxicity study and a prenatal developmental toxicity study performed with the NF, the Panel derives a safe level of 16.5 mg/kg body weight per day. The Panel concludes that the NF, freeze-dried mycelia of Antrodia camphorata, is safe at the proposed use level for individuals aged 14 years and above.
Collapse
|
5
|
Li TJ, Lin TW, Wu SP, Chu HT, Kuo YH, Chiou JF, Lu LS, Chen CC. Patient-Derived Tumor Chemosensitization of GKB202, an Antrodia Cinnamomea Mycelium-Derived Bioactive Compound. Molecules 2021; 26:molecules26196018. [PMID: 34641562 PMCID: PMC8512555 DOI: 10.3390/molecules26196018] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2021] [Revised: 09/29/2021] [Accepted: 09/29/2021] [Indexed: 01/14/2023] Open
Abstract
Oral cancers, hepatocellular carcinoma, and colorectal cancers are the three most common cancers, leading to 18,000 cases of cancer-related mortality in Taiwan per year. To bridge the gap towards clinical translation, we developed a circulating tumor cell (CTC) organoid culture workflow that efficiently expands CTC from patients to test Antrodia Cinnamomea mycelium-derived bioactive compounds. Three ACM-derived bioactive compounds were evaluated for tumor chemosensitization characteristics. Significant and consistent cytotoxic/5-FU sensitizing effects of GKB202 were found on 8 different patient-derived tumors. Acute toxicity profile and hepatic metabolism of GKB202 in rats suggest GKB202 is rapidly cleared by liver and is well tolerated up to the dose of 20 mg/kg. This comprehensive study provides new evidence that liquid fermentation of Antrodia cinnamomea mycelium (ACM) contains bioactive compounds that lead to effective control of CTC, especially when combined with 5-FU. Together, these data suggest ACM-derived GKB202 may be considered for further clinical investigation in the context of 5-FU-based combination therapy.
Collapse
Affiliation(s)
- Tsung-Ju Li
- Biotech Research Institute, Grape King Bio, Taoyuan 32542, Taiwan; (T.-J.L.); (T.-W.L.); (H.-T.C.); (Y.-H.K.)
| | - Ting-Wei Lin
- Biotech Research Institute, Grape King Bio, Taoyuan 32542, Taiwan; (T.-J.L.); (T.-W.L.); (H.-T.C.); (Y.-H.K.)
| | - Shih-Pei Wu
- CancerFree Biotech Ltd., Taipei City 106, Taiwan;
| | - Hsin-Tung Chu
- Biotech Research Institute, Grape King Bio, Taoyuan 32542, Taiwan; (T.-J.L.); (T.-W.L.); (H.-T.C.); (Y.-H.K.)
| | - Yu-Hsuan Kuo
- Biotech Research Institute, Grape King Bio, Taoyuan 32542, Taiwan; (T.-J.L.); (T.-W.L.); (H.-T.C.); (Y.-H.K.)
| | - Jeng-Fong Chiou
- Department of Radiation Oncology, Taipei Medical University Hospital, Taipei City 110, Taiwan;
- TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei City 110, Taiwan
- Department of Radiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei City 110, Taiwan
| | - Long-Sheng Lu
- Department of Radiation Oncology, Taipei Medical University Hospital, Taipei City 110, Taiwan;
- Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei City 110, Taiwan
- International Ph.D. Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei City 110, Taiwan
- International Ph.D. Program for Cell Therapy and Regenerative Medicine, College of Medicine, Taipei Medical University, Taipei City 11031, Taiwan
- Correspondence: (L.-S.L.); (C.-C.C.)
| | - Chin-Chu Chen
- Biotech Research Institute, Grape King Bio, Taoyuan 32542, Taiwan; (T.-J.L.); (T.-W.L.); (H.-T.C.); (Y.-H.K.)
- Department of Food Science, Nutrition, and Nutraceutical Biotechnology, Shih Chien University, Taipei City 104, Taiwan
- Institute of Food Science and Technology, National Taiwan University, Taipei City 10617, Taiwan
- Correspondence: (L.-S.L.); (C.-C.C.)
| |
Collapse
|
6
|
Chiang SS, Chen LS, Chu CY. Active food ingredients production from cold pressed processing residues of Camellia oleifera and Camellia sinensis seeds for regulation of blood pressure and vascular function. CHEMOSPHERE 2021; 267:129267. [PMID: 33338714 DOI: 10.1016/j.chemosphere.2020.129267] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/02/2020] [Revised: 12/04/2020] [Accepted: 12/07/2020] [Indexed: 06/12/2023]
Abstract
Hypertension is one of the most common illnesses worldwide. Accurate control of blood pressure can help reduce the incidence of complications. Nω-nitro-l-arginine methyl ester (l-NAME) is a nitric oxide synthase inhibitor that increases oxidative stress and inflammatory responses, activating the expression of transforming growth factor-beta (TGF-β), which thickens the vessel wall and ultimately contributes to hypertension. Studies have shown that seeds of Camellia oleifera Abel and Camellia sinensis (L). O. Kuntze (Oolong tea) possesses antibacterial, antioxidant, and anti-inflammatory functions. Therefore, this study aimed was to investigate the functional components in the seed pomace ethanol extracts of C. oleifera Abel (CPE) and Oolong tea (OPE) and to evaluate the ameliorative effects of CPE and OPE on oxidative stress, inflammation, and vascular remodeling in l-NAME induced hypertensive C57BL/6J mice. After 8 weeks of treatment, all CPE and OPE dose groups significantly reduced systolic and diastolic blood pressure, by over 30 mmHg and 15 mmHg, respectively. Additionally, CPE and OPE decreased transforming growth factor-beta (TGF-β) expression in the thoracic aortic and thoracic aortic intima-media thickness. Moreover, CPE and OPE decreased the malondialdehyde concentration in the liver by over 33%, as well as levels of tumor necrosis factor-α, interleukin 6, and interleukin-1β in the kidney and heart. Collectively, CPE and OPE can reduce oxidative stress and vascular remodeling, lowering blood pressure, and reducing the risk of cardiovascular disease.
Collapse
Affiliation(s)
- Shen-Shih Chiang
- Department of Food Science and Biotechnology, National Chung Hsing University, 40227, Taichung, Taiwan.
| | - Le-Shu Chen
- Department of Food Science and Biotechnology, National Chung Hsing University, 40227, Taichung, Taiwan.
| | - Chen-Yeon Chu
- Institute of Green Products, Feng Chia University, 40724, Taichung, Taiwan; Master's Program of Green Energy Science and Technology, Feng Chia University, 40724, Taichung, Taiwan.
| |
Collapse
|
7
|
A Pilot Study to Assess Food Safety and Potential Cholesterol-Lowering Efficacy of Antrodia cinnamomea Solid-State Cultivated Mycelium in Healthy Adults. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2020; 2020:5865764. [PMID: 32351598 PMCID: PMC7171625 DOI: 10.1155/2020/5865764] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/25/2019] [Revised: 02/07/2020] [Accepted: 02/25/2020] [Indexed: 12/16/2022]
Abstract
Antrodia cinnamomea is a Taiwanese medicinal mushroom with multiple pharmacological activities. Antrodia cinnamomea solid-state cultivated mycelium (LAC) exerts health-related effects in animal and cell models, but clinical data is limited. This study aimed to determine the safety and effects of LAC on human physiological functions. In an open-label, single-arm study, 32 healthy men and women ingested LAC capsules for three months. The subjects were monitored during the study and one month after the study end-point. LAC consumption did not significantly change fasting blood glucose, blood pressure, and triglyceride levels or liver and renal function indices. No adverse events occurred during the trial. Moreover, a significant change from baseline in total cholesterol levels was observed; men and women had decreases of 5.7% and 5.3%, respectively. Based on these, the ingestion of LAC-capsule has a considerable degree of safety and has the potential to reduce total cholesterol in healthy adults.
Collapse
|
8
|
The Effects of Ergosta-7,9(11),22-trien-3β-ol from Antrodia camphorata on the Biochemical Profile and Exercise Performance of Mice. Molecules 2019; 24:molecules24071225. [PMID: 30925792 PMCID: PMC6480148 DOI: 10.3390/molecules24071225] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2019] [Revised: 03/26/2019] [Accepted: 03/26/2019] [Indexed: 01/19/2023] Open
Abstract
Antrodia camphorata (AC) is a rare and unique mushroom that is difficult to cultivate. Previous studies have demonstrated the bioactivity of the compound Ergosta-7,9(11),22-trien-3β-ol (EK100) from AC in submerged culture. The purpose of this study is to evaluate the potential beneficial effects of EK100 on fatigue and ergogenic functions following physiological challenge. Male ICR (Institute of Cancer Research) mice were randomly divided into three groups (n = 8 per group) and orally administered EK100 for six weeks at 0 (Vehicle), 10 (EK100-1X), and 20 (EK100-2X) mg/kg/day. The six-week Ek100 supplementation significantly increased grip strength (p = 0.0051) in trend analysis. Anti-fatigue activity was evaluated using 15-min. acute exercise testing and measuring the levels of serum lactate, ammonia, glucose, blood urea nitrogen (BUN), and creatine kinase (CK) after a 15-min. swimming exercise. Our results indicate that AC supplementation leads to a dose-dependent decrease in serum lactate, ammonia, BUN, and CK activity after exercise and significantly increases serum glucose and glycogen content in liver tissues. Biochemical and histopathological data demonstrated that long term daily administration of EK100 for over six weeks (subacute toxicity) was safe. EK100’s anti-fatigue properties appear to be through the preservation of energy storage, increasing blood glucose and liver glycogen content, and decreasing the serum levels of lactate, ammonia, BUN, and CK. EK100 could potentially be used to improve exercise physiological adaptation, promote health, and as a potential ergogenic aid in combination with different nutrient strategies.
Collapse
|
9
|
Chen SY, Lee YR, Hsieh MC, Omar HA, Teng YN, Lin CY, Hung JH. Enhancing the Anticancer Activity of Antrodia cinnamomea in Hepatocellular Carcinoma Cells via Cocultivation With Ginger: The Impact on Cancer Cell Survival Pathways. Front Pharmacol 2018; 9:780. [PMID: 30072899 PMCID: PMC6058215 DOI: 10.3389/fphar.2018.00780] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2018] [Accepted: 06/26/2018] [Indexed: 01/10/2023] Open
Abstract
Antrodia cinnamomea (AC) is a medicinal fungal species that has been widely used traditionally in Taiwan for the treatment of diverse health-related conditions including cancer. It possesses potent anti-inflammatory and antioxidant properties in addition to its ability to promote cancer cell death in several human tumors. Our aim was to improve the anticancer activity of AC in hepatocellular carcinoma (HCC) through its cocultivation with ginger aiming at tuning the active ingredients. HCC cell lines, Huh-7 and HepG2 were used to study the in vitro anticancer activity of the ethanolic extracts of AC (EAC) alone or after the cocultivation in presence of ginger (EACG). The results indicated that the cocultivation of AC with ginger significantly induced the production of important triterpenoids and EACG was significantly more potent than EAC in targeting HCC cell lines. EACG effectively inhibited cancer cells growth via the induction of cell cycle arrest at G2/M phase and induction of apoptosis in Huh-7 and HepG2 cells as indicated by MTT assay, cell cycle analysis, Annexin V assay, and the activation of caspase-3. In addition, EACG modulated cyclin proteins expression and mitogen-activated protein kinase (MAPK) signaling pathways in favor of the inhibition of cancer cell survival. Taken together, the current study highlights an evidence that EACG is superior to EAC in targeting cancer cell survival and inducing apoptotic cell death in HCC. These findings support that EACG formula can serve as a potential candidate for HCC adjuvant therapy.
Collapse
Affiliation(s)
- San-Yuan Chen
- Department of Chinese Medicine, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi, Taiwan.,Institute of Molecular Biology, National Chung Cheng University, Chiayi, Taiwan
| | - Ying-Ray Lee
- Department of Medical Research, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi, Taiwan
| | - Ming-Chia Hsieh
- Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan
| | - Hany A Omar
- Sharjah Institute for Medical Research and College of Pharmacy, University of Sharjah, Sharjah, United Arab Emirates.,Department of Pharmacology, Faculty of Pharmacy, Beni-Suef University, Beni Suef, Egypt
| | - Yen-Ni Teng
- Department of Biological Sciences and Technology, National University of Tainan, Tainan, Taiwan
| | - Ching-Yen Lin
- Department of Medical Research, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi, Taiwan
| | - Jui-Hsiang Hung
- Drug Discovery and Development Center, Chia Nan University of Pharmacy and Science, Tainan, Taiwan.,Department of Biotechnology, Chia Nan University of Pharmacy and Science, Tainan, Taiwan
| |
Collapse
|